Subscribe
shutterstock_1113551483_sharafmaksumov
sharafmaksumov / Shutterstock.com
12 February 2019Americas

Clarivate announces new Life Science Alliances programme

Global information company  Clarivate Analytics has launched a “Life Science Alliances Program” to provide drug and medical device developers a new way to advance their research and development.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Seven new drugs to join $1bn club by 2021, says Clarivate
21 March 2019   Seven new drugs are forecasted to achieve annual sales of $1 billion or more by 2023, according to a new report.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

More on this story

Big Pharma
Seven new drugs to join $1bn club by 2021, says Clarivate
21 March 2019   Seven new drugs are forecasted to achieve annual sales of $1 billion or more by 2023, according to a new report.

More on this story

Big Pharma
Seven new drugs to join $1bn club by 2021, says Clarivate
21 March 2019   Seven new drugs are forecasted to achieve annual sales of $1 billion or more by 2023, according to a new report.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent